Loading...

SYRE SPYRE THERAPEUTICS INC Expansion Plans 8-K Filing

SPYR

SYR

SPYRE THERAPEUTICS INC

(SYRE)

2025 8-K

Trial Results Announced

Stock Offering Announcement

Financial Update

Financial Statements

Product Expansion

Financial Statements

Financial Results

Financial Update

Financial Restatement

Positive Trial Results

Financial Results

License Agreement

Correction of Clerical Error

Earnings Reports

Regulation FD Disclosure

License Agreements and Dire...

Earnings Reports

Unregistered Sales of Equit...

Private Placement

Results of Operations and F...

Indemnification Agreement, ...

Private Placement

CEO Appointment

Increase in Authorized Shares

Form 8-K Filing

Earnings Reports

Corporate Presentation Update

Appointment of Principal Ex...

Acquisition of Spyre Therap...

Entry into Material Definit...

Financial Results Announcement

Termination of Lease Agreement

Asset Purchase Agreement wi...

Merger and Private Placement

Acquisition and Private Pla...

Annual Meeting of Stockholders

Management Changes

Financial Results Announcement

Financial Update

Restructuring and Departure...

FDIC closes SVB and transfe...

Financial Results and Corpo...

Regulation FD Disclosure

Departure of Directors or C...

External Links:

On November 4, 2025, Spyre Therapeutics, Inc. reported positive interim Phase 1 results for SPY003, which targets IL-23, showing safety and a long half-life of 85 days in a trial with 59 participants. This is a significant event reflecting potential advancements in inflammatory bowel disease treatment.

AI Assistant

SPYRE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.